Reproducibility of immunohistochemical scoring for epidermal growth factor receptor expression in non-small cell lung cancer: Round robin test

Archives of Pathology and Laboratory Medicine

Volumn 137, Issue 9, 2013, Pages 1255-1261

  Rüschoff, Josef ^a,b   Kerr, Keith M ^c   Grote, Hans J ^d   Middel, Peter ^a,b   Von Heydebreck, Anja ^d   Alves, Venâncio A ^e   Baldus, Stephan E ^f   Büttner, Reinhard ^g   Carvalho, Lina ^h   Fink, Ludger ⁱ   Jochum, Wolfram ^j   Lo, Anthony W I ^k   López Ríos, Fernando ^l   Marx, Alexander ^m   Molina, Thierry J ⁿ   Olszewski, Wlodzimierz T ^o   Rieker, Ralf J ^p   Volante, Marco ^q   Thunnissen, Erik ^r   Wrba, Fritz ^s   Celik, Ilhan ^d   Störkel, Stephan ^t   more..

^a Institute of Pathology Nordhessen   (Germany)

^b Targos Advance   (Germany)

^c ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^d MERCK KGAA   (Germany)

^e UNIVERSITY OF SÃO PAULO   (Brazil)

^f UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^g UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^h CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

ⁱ Institute of Pathology and Cytology   (Germany)

^j Institute of Pathology   (Switzerland)

^k CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^l Hospital Universitario Madrid Sanchinarro   (Spain)

^m UNIVERSITY OF HEIDELBERG   (Germany)

ⁿ UNIVERSITÉ PARIS DESCARTES   (France)

^o INSTITUTE OF ONCOLOGY   (Poland)

^p UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^q UNIVERSITY OF TURIN   (Italy)

^r VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^s Clinical Institute of Pathology   (Austria)

^t UNIVERSITY OF WITTEN HERDECKE   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; TUMOR MARKER;

ARTICLE; FEASIBILITY STUDY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METABOLISM; MIDDLE AGED; OBSERVER VARIATION; PATHOLOGY; PROSPECTIVE STUDY; REPRODUCIBILITY; TISSUE MICROARRAY;

CARCINOMA, NON-SMALL-CELL LUNG; FEASIBILITY STUDIES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MIDDLE AGED; OBSERVER VARIATION; PROSPECTIVE STUDIES; RECEPTOR, EPIDERMAL GROWTH FACTOR; REPRODUCIBILITY OF RESULTS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84885117081     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2012-0605-OA     Document Type: Article

References (19)

1. Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet. 2009;373(9674):1525-1531.
2. Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst. 2005;97(9):643-655. (Pubitemid 40812628)
3. Felip E, Rojo F, Reck M, et al. A phase II pharmacodynamic study of erlotinib in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy. Clin Cancer Res. 2008;14(12):3867- 3874.
4. Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol. 2003; 21(20):3798-3807. (Pubitemid 46606235)
5. Lee HJ, Xu X, Choe G, et al. Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas: comparison of four commercially available antibodies by immunohistochemistry and fluorescence in situ hybridization study. Lung Cancer. 2010;68(3):375-382.
6. Lazar AA, Cole BF, Bonetti M, Gelber RD. Evaluation of treatment-effect heterogeneity using biomarkers measured on a continuous scale: subpopulation treatment effect pattern plot. J Clin Oncol. 2010;28(29):4539-4544.
7. Pirker R, Pereira J, von Pawel J, et al. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol. 2012;13(1):33-42.
8. Ruschoff J, Dietel M, Baretton G, et al. HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch. 2010;457(3):299-307.
9. Cohen J. A coefficient of agreement for nominal scales. Educ Psychol Meas. 1960;20:37-46.
10. Alymani NA, Smith MD, Williams DJ, Petty RD. Predictive biomarkers for personalised anti-cancer drug use: discovery to clinical implementation. Eur J Cancer. 2010;46(5):869-879.
11. Andrews J, Yeh P, Pao W, Horn L. Molecular predictors of response to chemotherapy in non-small cell lung cancer. Cancer J. 2011;17(2):104-113.
12. Tan DS, Thomas GV, Garrett MD, et al. Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development. Cancer J. 2009;15(5): 406-420.
13. Prinsen CF, Klaassen CH, Thunnissen FB. Microarray as a model for quantitative visualization chemistry. Appl Immunohistochem Mol Morphol. 2003;11(2):168-173. (Pubitemid 36749572)
14. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999; 17(5):1474-1481. (Pubitemid 29220854)
15. Allred DC. Issues and updates: evaluating estrogen receptor-alpha, progesterone receptor, and HER2 in breast cancer. Mod Pathol. 2010;23(suppl 2):S52-S59.
16. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25(1):118-145. (Pubitemid 350003059)
17. Liang Z, Zhang J, Zeng X, Gao J, Wu S, Liu T. Relationship between EGFR expression, copy number and mutation in lung adenocarcinomas. BMC Cancer. 2010;10:376.
18. O'Byrne KJ, Gatzemeier U, Bondarenko I, et al. Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study. Lancet Oncol. 2011;12(8):795-805.
19. Pierceall WE, Wolfe M, Suschak J, et al. Strategies for H-score normalization of preanalytical technical variables with potential utility to immunohistochemical-based biomarker quantitation in therapeutic response diagnostics. Anal Cell Pathol (Amst). 2011;34(3):159-168.